(Total Views: 350)
Posted On: 04/30/2018 9:27:06 PM
Post# of 72446
I was reading the Evonik news release again, very slowly, and came across the following statement from Dr. Bertolino:
“We anticipate this drug substance, to be manufactured to the high standards and philosophy of Quality by Design (QbD), will provide for our long-term needs across multiple anchored clinical indications in the Brilacidin Franchise.”
The term "across multiple anchored clinical indications in the Brilacidin Franchise" to me means that they will be developing and/or manufacturing Brilacidin in more than one form, possibly powder, pill, and topical cream.
Anybody else think this is possible or do most think it is just for B in sachet powder formulation?
“We anticipate this drug substance, to be manufactured to the high standards and philosophy of Quality by Design (QbD), will provide for our long-term needs across multiple anchored clinical indications in the Brilacidin Franchise.”
The term "across multiple anchored clinical indications in the Brilacidin Franchise" to me means that they will be developing and/or manufacturing Brilacidin in more than one form, possibly powder, pill, and topical cream.
Anybody else think this is possible or do most think it is just for B in sachet powder formulation?
(1)
(0)
